361 reports of this reaction
1.9% of all AMLODIPINE BESYLATE AND VALSARTAN reports
#10 most reported adverse reaction
DYSPNOEA is the #10 most commonly reported adverse reaction for AMLODIPINE BESYLATE AND VALSARTAN, manufactured by Novartis Pharmaceuticals Corporation. There are 361 FDA adverse event reports linking AMLODIPINE BESYLATE AND VALSARTAN to DYSPNOEA. This represents approximately 1.9% of all 18,550 adverse event reports for this drug.
Patients taking AMLODIPINE BESYLATE AND VALSARTAN who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for AMLODIPINE BESYLATE AND VALSARTAN, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for AMLODIPINE BESYLATE AND VALSARTAN:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 361 FDA reports for AMLODIPINE BESYLATE AND VALSARTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.9% of all adverse event reports for AMLODIPINE BESYLATE AND VALSARTAN, making it a notable side effect.
If you experience dyspnoea while taking AMLODIPINE BESYLATE AND VALSARTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.